Success Metrics

Clinical Success Rate
82.4%

Based on 14 completed trials

Completion Rate
82%(14/17)
Active Trials
2(10%)
Results Posted
50%(7 trials)
Terminated
3(14%)

Phase Distribution

Ph phase_4
4
19%
Ph phase_2
4
19%
Ph phase_1
5
24%
Ph not_applicable
6
29%
Ph early_phase_1
2
10%

Phase Distribution

7

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution21 total trials
Early Phase 1First-in-human
2(9.5%)
Phase 1Safety & dosage
5(23.8%)
Phase 2Efficacy & side effects
4(19.0%)
Phase 4Post-market surveillance
4(19.0%)
N/ANon-phased studies
6(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.4%

14 of 17 finished

Non-Completion Rate

17.6%

3 ended early

Currently Active

2

trials recruiting

Total Trials

21

all time

Status Distribution
Active(3)
Completed(14)
Terminated(3)
Other(1)

Detailed Status

Completed14
Terminated3
Recruiting2
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
2
Success Rate
82.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (9.5%)
Phase 15 (23.8%)
Phase 24 (19.0%)
Phase 44 (19.0%)
N/A6 (28.6%)

Trials by Status

unknown15%
recruiting210%
terminated314%
not_yet_recruiting15%
completed1467%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT06972407Phase 2

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Not Yet Recruiting
NCT06967558Phase 2

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Recruiting
NCT01803451Early Phase 1

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

Recruiting
NCT02844907Phase 4

Regulation of Insulin Secretion by the GLP-1 Receptor

Terminated
NCT02550145Phase 1

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

Terminated
NCT02996812Phase 1

Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia

Completed
NCT03101930Phase 4

Cardiovascular Effects of GLP-1 Receptor Activation

Completed
NCT03373435Phase 2

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Completed
NCT00835328Phase 1

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

Terminated
NCT03241303Not Applicable

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

Completed
NCT02971631Not Applicable

Gastrectomy, Eating Behaviour and GLP-1

Completed
NCT02170870Phase 2

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

Completed
NCT03246451Not Applicable

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

Completed
NCT01701973Phase 4

Effect of DPP4 Inhibition on Growth Hormone Secretion

Completed
NCT02746757Not Applicable

Glucagon Like Peptide-1 in Remote Ischemic Conditioning

Completed
NCT01795144Phase 1

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Completed
NCT02639130Phase 4

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Completed
NCT02336659Not Applicable

Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery

Completed
NCT01843855Early Phase 1

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

Completed
NCT01900340Phase 1

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
21